{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:58:10Z","timestamp":1769630290724,"version":"3.49.0"},"reference-count":52,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Clinical trials and real-life studies have granted the efficacy and safety of dolutegravir and lamivudine (DTG\/3TC) in na\u00efve and experienced people living with HIV (PLWH), but there are no long-term data in elderly people. We herein describe our real-life cohort of PLWH who were \u226565 years of age (PLWH \u2265 65) who started or were switched to DTG\/3TC, single-tablet regimen, or DTG plus 3TC. Methods: We considered laboratory\/clinical parameter changes from the baseline to the last follow-up time point available for each person by the paired Wilcoxon test and analyzed factors associated with virological failure (VF) and discontinuation. Results: We included 112 PLWH with a median age of 66 (IQR: 65\u201370) years, 77.6% males; 84.8% of people had multimorbidity, 34.8% were on polypharmacy, and only 5.4% were na\u00efve to treatment. Reasons to be switched to DTG\/3TC were: abacavir removal (38.7%), treatment simplification (33.1%), and PI discontinuation (28.2%). The median treatment durability was 6 (IQR: 5.4\u20137) years. No significant changes were detected in metabolic, renal, immunological, or cardiovascular biomarkers during follow-up. HIV RNA undetectability was maintained in 104 (92.8%) individuals for whom follow-up evaluation was available. We observed eight discontinuations (two deaths, two VFs, two early intolerances, one significant weight gain, and one switch to long-acting therapy). No factors were significantly associated with VF or discontinuation. Conclusions: This is the first study on DTG\/3TC in PLWH \u2265 65 with a follow-up longer than 5 years. DTG\/3TC was found to be safe and effective, neutral on metabolic parameters, and with a low discontinuation rate for toxicity or VF.<\/jats:p>","DOI":"10.3390\/v15081740","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:06:16Z","timestamp":1692097576000},"page":"1740","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"first","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolita","family":"Sasset","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuele","family":"Gardin","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Leoni","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-719X","authenticated-orcid":false,"given":"Mattia","family":"Trunfio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, 10149 Turin, Italy"},{"name":"HIV Neurobehavioral Research Program, Departments of Neurosciences and Psychiatry, School of Medicine, University of California, San Diego, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-1505","authenticated-orcid":false,"given":"Daniele","family":"Mengato","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Agostini","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Vania","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"},{"name":"Infectious Disease Unit, Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Putaggio","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-2945","authenticated-orcid":false,"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital, 35128 Padua, Italy"},{"name":"Department of Molecular Medicine, University of Padua, 35131 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0703-839","article-title":"HIV and AIDS: 20 years of science","volume":"9","author":"Fauci","year":"2003","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort Collaboration (2017). Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV, 4, e349\u2013e356.","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(2015). The end of AIDS?. Lancet HIV, 2, e71.","DOI":"10.1016\/S2352-3018(15)00029-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/S2352-3018(17)30155-8","article-title":"New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004\u20132015: An analysis of surveillance data","volume":"4","author":"Tavoschi","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_6","unstructured":"European Centre for Disease Prevention and Control (2023, June 10). HIV\/AIDS Surveillance in Europe 2021 (2020 Data), Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/2021-Annual_HIV_Report_0.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/aid.2021.0083","article-title":"Evaluation of a Clinic Dedicated to People Aging with HIV at Chelsea and Westminster Hospital: Results of a 10-Year Experience","volume":"38","author":"Pereira","year":"2022","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S2352-3018(22)00066-2","article-title":"Delivering specialised care to people ageing with HIV in the UK: Experience and evolution of services from 2009 to 2019","volume":"9","author":"Milinkovic","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pourcher, V., Gourmelen, J., Bureau, I., and Bouee, S. (2020). Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243529"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Roomaney, R.A., van Wyk, B., and Pillay-van Wyk, V. (2022). Increased Risk of HIV Comorbidities in Older Adults. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19042359"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/09540121.2021.1935438","article-title":"Factors associated with overweight\/obesity in a cohort of people living with HIV over 50 years of age","volume":"34","author":"Mazzitelli","year":"2022","journal-title":"AIDS Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults with HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living with Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","unstructured":"European AIDS Clinical Society (2023, June 10). HIV Guidelines (Version 11.1). Available online: https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf."},{"key":"ref_16","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2023, June 10). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104552","DOI":"10.1016\/j.antiviral.2019.104552","article-title":"Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected na\u00efve patients: Results from a multicenter cohort study","volume":"169","author":"Rossetti","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/QAI.0000000000002787","article-title":"Five Years with Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J Acquir. Immune Defic. Syndr."},{"key":"ref_19","unstructured":"(2023, June 10). Gazzetta Ufficiale della Repubblica Italiana\u2014Serie Generale\u2014Anno 149\u00b0\u2014Numero 76. 31\/03\/2008. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2008\/03\/31\/76\/sg\/pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int."},{"key":"ref_21","first-page":"s176","article-title":"Obesity: Definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Masnoon, N., Shakib, S., Kalisch-Ellett, L., and Caughey, G.E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatr., 17.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Guaraldi, G., Malagoli, A., Calcagno, A., Mussi, C., Celesia, B.M., Carli, F., Piconi, S., De Socio, G.V., Cattelan, A.M., and Orofino, G. (2018). The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: A cross sectional study of people aged 65\u201374 years and more than 75 years. BMC Geriatr., 18.","DOI":"10.1186\/s12877-018-0789-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/QAD.0000000000002403","article-title":"Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV","volume":"33","author":"Mazzitelli","year":"2019","journal-title":"AIDS"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Fusco, P., Brogna, M., Vallone, A., D\u2019Argenio, L., Beradelli, G., Foti, G., Mangano, C., Carpentieri, M.S., and Cosco, L. (2022). Weight of Clinical and Social Determinants of Metabolic Syndrome in People Living with HIV. Viruses, 14.","DOI":"10.3390\/v14061339"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1097\/QAD.0000000000001478","article-title":"Clinical implications of aging with HIV infection: Perspectives and the future medical care agenda","volume":"31","author":"Guaraldi","year":"2017","journal-title":"AIDS"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/QAI.0b013e31825a3668","article-title":"HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group","volume":"60","author":"High","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/QAD.0b013e3283558500","article-title":"Lessons learned from the first wave of aging with HIV","volume":"26","author":"Justice","year":"2012","journal-title":"AIDS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/21505594.2016.1245269","article-title":"Assessment of geriatric syndromes and physical function in people living with HIV","volume":"8","author":"Greene","year":"2017","journal-title":"Virulence"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e28488","DOI":"10.1097\/MD.0000000000028488","article-title":"Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis","volume":"100","author":"Mazzitelli","year":"2021","journal-title":"Medicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine"},{"key":"ref_33","unstructured":"Sammet, S., Touzeau-R\u00f6mer, V., Wolf, E., Schenk-Westkamp, P., Romano, B., Gersbacher, E., Kastenbauer, U., Boesecke, C., Rockstroh, J., and Scholten, S. The DoDo experience: An alternative antiretroviral 2-drug regimen of doravirine and dolutegravir, Infection, in press."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/09564624221116533","article-title":"HIV treatment with dolutegravir and doravirine: Rationale for selection and clinical outcomes in a highly treatment experienced population","volume":"33","author":"Denyer","year":"2022","journal-title":"Int. J. STD AIDS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2014Naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"ref_36","unstructured":"Palmier, E., De Miguel, R., Montejano, R., Busca, C., Mican, R., Ramos, L., Cadi\u00f1anos, J., Serrano, L., Bernardino, J.I., and P\u00e9rez-Valero, I. Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study, HIV Med., in press."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2018","journal-title":"F1000Research"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: A modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/25787489.2021.1941672","article-title":"Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: Analyses of 6 phase III clinical trials","volume":"22","author":"Spinelli","year":"2021","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people >\/=65 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/QAD.0000000000002293","article-title":"Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV","volume":"33","author":"Underwood","year":"2019","journal-title":"AIDS"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkx169","article-title":"Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study","volume":"72","author":"Nozza","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"DAD Study Group, Friis-M\u00f8ller, N., Reiss, P., Sabin, C.A., Weber, R., d\u2019Arminio Monforte, A., El-Sadr, W., Thi\u00e9baut, R., De Wit, S., and Kirk, O. (2007). Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med., 356, 1723\u20131735.","DOI":"10.1056\/NEJMoa062744"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2020.0078","article-title":"Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort","volume":"37","author":"Ciccullo","year":"2021","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e25899","DOI":"10.1002\/jia2.25899","article-title":"Weight gain during the dolutegravir transition in the African Cohort Study","volume":"25","author":"Esber","year":"2022","journal-title":"J. Int. AIDS Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36469\/30184","article-title":"Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors","volume":"9","author":"Chen","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): Week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1097\/QAD.0000000000001596","article-title":"Dolutegravir and neuropsychiatric adverse events: A continuing debate","volume":"31","author":"Cailhol","year":"2017","journal-title":"AIDS"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/QAD.0000000000001459","article-title":"Neuropsychiatric adverse effects on dolutegravir: An emerging concern in Europe","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciy426","article-title":"Increased Dolutegravir Peak Concentrations in People Living with Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition","volume":"68","author":"Elliot","year":"2019","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:33:43Z","timestamp":1760128423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["v15081740"],"URL":"https:\/\/doi.org\/10.3390\/v15081740","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]}}}